Abstract |
We identified association of restless legs syndrome (RLS) with PTPRD at 9p23-24 in 2,458 affected individuals and 4,749 controls from Germany, Austria, Czechia and Canada. Two independent SNPs in the 5' UTR of splice variants expressed predominantly in the central nervous system showed highly significant P values (rs4626664, P(nominal/lambda corrected) = 5.91 x 10(-10), odds ratio (OR) = 1.44; rs1975197, P(nominal/lambda corrected) = 5.81 x 10(-9), OR = 1.31). This work identifies PTPRD as the fourth genome-wide significant locus for RLS.
|
Authors | Barbara Schormair, David Kemlink, Darina Roeske, Gertrud Eckstein, Lan Xiong, Peter Lichtner, Stephan Ripke, Claudia Trenkwalder, Alexander Zimprich, Karin Stiasny-Kolster, Wolfgang Oertel, Cornelius G Bachmann, Walter Paulus, Birgit Högl, Birgit Frauscher, Viola Gschliesser, Werner Poewe, Ines Peglau, Pavel Vodicka, Jana Vávrová, Karel Sonka, Sona Nevsimalova, Jacques Montplaisir, Gustavo Turecki, Guy Rouleau, Christian Gieger, Thomas Illig, H-Erich Wichmann, Florian Holsboer, Bertram Müller-Myhsok, Thomas Meitinger, Juliane Winkelmann |
Journal | Nature genetics
(Nat Genet)
Vol. 40
Issue 8
Pg. 946-8
(Aug 2008)
ISSN: 1546-1718 [Electronic] United States |
PMID | 18660810
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 5' Untranslated Regions
- PTPRD protein, human
- Receptor-Like Protein Tyrosine Phosphatases, Class 2
|
Topics |
- 5' Untranslated Regions
(genetics)
- Austria
- Canada
- Case-Control Studies
- Czech Republic
- Genetic Predisposition to Disease
- Germany
- Humans
- Polymorphism, Single Nucleotide
- Receptor-Like Protein Tyrosine Phosphatases, Class 2
(genetics)
- Restless Legs Syndrome
(genetics)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|